9 directorsName hiddenVisible after signing in and 8 others
Owners3 names in the annual accounts
17.16%Name hiddenVisible after signing in and 1 other
Documentsfilings and deeds
21-05-202671 days before the deadline
2025financial year
Loss of €7.7mStaff from 19.5 FTE to 17.1 FTECapital decrease to €15,770,445.9219-06Company renamed from AstriVax to AstriVax Therapeutics28-03Name hiddenVisible after signing in resigns as director07-02Equity from €18.3m to €10.7m
AstriVax Therapeutics was awarded €5.9m in Flemish support from 2022 to 2025, mostly under Onderzoeksproject.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 132 companies had the same profile as AstriVax Therapeutics has now. Each dot is one company, two years later.
93.2%
were still trading
3.8%
stopped another way
3.0%
went bankrupt
Small
2 to 5 years old
solvency 30% or more
a loss of 10% of the balance sheet or more
Test of the method
The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 132 companies, not a prediction for AstriVax Therapeutics. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Name hiddenVisible after signing in 17.16%equity €124.0m (2025) · annual accounts 2025 of Hidden nameVisible after signing in+
Name after signing inVisible after signing in 14.3%score XXVisible after signing inequity €30.4m (2025) · annual accounts 2025 of Hidden nameVisible after signing in
Name after signing inVisible after signing in 14.3%score XXVisible after signing inequity €51.8m (2025) · annual accounts 2025 of Hidden nameVisible after signing in
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0787990881
Capital decrease to €15,770,445.92
The capital fell from €26,546,226.67 to €15,770,445.92 · Hidden nameVisible after signing in appointed as director · General meeting of 10-06-2025 · Gazette deed
Company renamed from AstriVax to AstriVax Therapeutics
General meeting of 18-03-2025 · Gazette deed
Name after signing inVisible after signing in resigns as directorName hiddenVisible after signing in appointed as director · Board meeting of 01-10-2024 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as AstriVax Therapeutics: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €5.7m and €18m, founded between 2019 and 2021.
The annual accounts of AstriVax Therapeutics for financial year 2025 show a net loss of 61% of total assets. The 2025 annual accounts show equity of €10.7m and a net result of -€7.7m.
Equity has been shrinking by about 14% per year since 2023. Its solvency ranks better than 81% of 121 sector peers (NACE 72) in financial year 2025.
The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.